ASHLEY BEMO: Open Payments
NPI 1922303734 · NEODESHA, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$294 in 17 payments from 11 companies in 2025. Trend: 2023 $104 · 2024 $300 · 2025 $294
Food & beverage: $294
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $54 |
| Novo Nordisk Inc | 3 | $52 |
| AstraZeneca Pharmaceuticals LP | 3 | $43 |
| Dexcom, Inc. | 1 | $24 |
| Amgen Inc. | 1 | $22 |
| Boston Scientific Corporation | 1 | $19 |
| Insulet Corporation | 1 | $18 |
| Novartis Pharmaceuticals Corporation | 1 | $17 |
| GlaxoSmithKline, LLC. | 1 | $16 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
Products named: CAPLYTA, Wegovy, DEXCOM G7 GSS (161), EVENITY, WATCHMAN FLX, Omnipod, LEQVIO, TRELEGY ELLIPTA.
Industry payments across KS — which companies pay providers there.
